Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

Clime: CLL Immune Micro-Environment and Risk of Infections Pre- and Post-Diagnosis: A Population-Based Study

Versha Banerji, David E Dawe, Lin Xue, Oliver Bucher, Lin Yang, James B. Johnston, Spencer Bruce Gibson, Kathleen Decker

Blood (2023) 142 (Supplement 1): 7396.

https://doi.org/10.1182/blood-2023-187573

Published: 2023

Journal Articles

IL-4 Mediated Upregulation of AMPK/SIRT1/PGC-1α Signalling Pathway Is Bypassed By Mitochondrial Complex I Downregulation By NAMPT Inhibition in Venetoclax and Ibrutinib Treated CLL Cells

Subir Roy Chowdhury, Cheryl Peltier, Eileen M. McMillan-Ward, Ryan Saleh, Tricia Choquette, Maxim Skorodinsky, Kira Peters, Edwin Nguyen, Amandeep Singh, Eric D. Bouchard, James B. Johnston, Aaron Marshall, James Thliveris, Spencer Bruce Gibson, Sara J. Israels, Versha Banerji

Blood (2021) 138 (Supplement 1): 2616.

https://doi.org/10.1182/blood-2021-146947

Published: 2021

Journal Articles

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Blood (2021) 137 (15): 2046–2056.

https://doi.org/10.1182/blood.2020006322

Published: 2021

Includes: Supplemental data

Journal Articles

Ibrutinib in Combination with Venetoclax Decreases Mitochondrial Bioenergetics through the Impaired BTK, AKT and AMPK/SIRT/PGC-1α Signaling Pathway in CLL

Subir Roy Chowdhury, MD PhD, Amandeep Singh, MSc, Edwin Nguyen, Aaron Marshall, PhD, James B. Johnston, MD, Spencer Bruce Gibson, PhD, Versha Banerji, MD

Blood (2019) 134 (Supplement_1): 1282.

https://doi.org/10.1182/blood-2019-127562

Published: 2019

Journal Articles

A Descriptive Analysis of Obinutuzumab Usage in a Single Canadian Centre

Nicole Bourrier, BSc, Ivan Landego, MD, Mandy Squires, CCRP, HIT, Oliver Bucher, Zeb Aurangzeb, Erin Streu, MSN, RN, CON (C), Theresa Whiteside, RN, BN, CON (C), Irena Hibbert, RN, BN, CON (C), Marc Geirnaert, BSc Pharm, David Dawe, MD FRCPC, Spencer Bruce Gibson, PhD, James B. Johnston, MD FRCP, Versha Banerji, MD

Blood (2018) 132 (Supplement 1): 5838.

https://doi.org/10.1182/blood-2018-99-113422

Published: 2018

Journal Articles

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

Blood (2018) 131 (23): 2541–2551.

https://doi.org/10.1182/blood-2017-11-814608

Published: 2018

Includes: Supplemental data

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

Revelance of Gammaglobulin Levels at Diagnosis and during Disease Course in Chronic Lymphocytic Leukemia

Erin Streu, RN MN CON(C), Jayce Bi, Mandy DeSousa, Versha Banerji, MD FRCP, Dhali H.S. Dhaliwal, MD FRCP, Sara Beiggi, PhD, James B. Johnston, MD FRCP

Blood (2016) 128 (22): 5561.

https://doi.org/10.1182/blood.V128.22.5561.5561

Published: 2016

Journal Articles

Incidence and Implications of Skin Cancers in Cancercare Manitoba Chronic Lymphocytic Leukemia (CLL) Clinic Patients

Sara Beiggi, PhD, Mohammad Pannu, Versha Banerji, MD FRCP, Dhali H.S. Dhaliwal, MD FRCP, Spencer B. Gibson, PhD, Marni Wiseman, MD FRCP, James B. Johnston, MD FRCP

Blood (2016) 128 (22): 4359.

https://doi.org/10.1182/blood.V128.22.4359.4359

Published: 2016

Journal Articles

High Cumulative Illness Rating Scale (CIRS) Score in CLL Correlates with Short CLL Telomere Length and Decreased Survival

Lin Yang, Sara Beiggi, PhD, Yunli Zhang, Sara Kost, Robert Schmidt, BSc, Gangimeg Ishdorj, Dhali H.S. Dhaliwal, MD FRCP, Versha Banerji, MD FRCP, Sabine Mai, PhD, Spencer B. Gibson, PhD, James B. Johnston, MD FRCP

Blood (2016) 128 (22): 4362.

https://doi.org/10.1182/blood.V128.22.4362.4362

Published: 2016

Journal Articles

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Harminder Paul, Susi Snitzler, RN, Lisa W Le, MSc, Ellen Nong Wei, Anthea Lau, James B Johnston, MD, Spencer B. Gibson, PhD, Michelle L. Queau, B.Sc, Suzanne Trudel, MD

Blood (2015) 126 (23): 4163.

https://doi.org/10.1182/blood.V126.23.4163.4163

Published: 2015

Journal Articles

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Susi Snitzler, RN, Olga Levina, RN, Tong (Trina) Wang, RN, Lisa W Le, MSc, Harminder Paul, Ellen Nong Wei, Anthea Lau, Michelle Queau, James B Johnston, MD, Suzanne Trudel, MD, Deborah A Smith

Blood (2015) 126 (23): 1742.

https://doi.org/10.1182/blood.V126.23.1742.1742

Published: 2015

Journal Articles

Clinical Impact of Telomere Shortening in Normal and Leukemia Cells in Chronic Lymphocytic Leukemia

Lin Yang, MD PhD, Sara Beiggi, PhD, Yunli Zhang, Robert Schmidt, Spencer B Gibson, PhD, James B. Johnston, MD

Blood (2014) 124 (21): 5641.

https://doi.org/10.1182/blood.V124.21.5641.5641

Published: 2014

Journal Articles

Lysosome Membrane Permeabilization Causes Cell Death in Primary Chronic Lymphocytic Leukemia Cells

Rebecca Dielschneider, BSc, Hannah Eisenstat, James B. Johnston, MD, Spencer B Gibson, PhD

Blood (2014) 124 (21): 930.

https://doi.org/10.1182/blood.V124.21.930.930

Published: 2014

Journal Articles

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Christine I. Chen, MD, Susi Snitzler, RN, Trina Wang, RN, Harminder Paul, Lisa W Le, Ellen Nong Wei, MSc, Anthea Lau, Deborah A Smith, PharmD, Michelle Brown, James B Johnston, MD, Suzanne Trudel, MD, MSC, FRCPC

Blood (2013) 122 (21): 4175.

https://doi.org/10.1182/blood.V122.21.4175.4175

Published: 2013

Journal Articles

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Ethan Toumishey, B. Sc, Angeli Prasad, CCRP, Gregory S. Dueck, MD, MSc, BSc, FRCPC, Neil Chua, MD, FRCPC, Daygen Finch, MD, Douglas A. Stewart, MD, FRCPC, Darrell J. White, MD, Richard H. van der Jagt, MD, FRCPC, James B Johnston, MD, Andrew R Belch, MD, Tony Reiman, MD

Blood (2013) 122 (21): 4376.

https://doi.org/10.1182/blood.V122.21.4376.4376

Published: 2013

Journal Articles

Jump-starting the T cells in CLL

James B. Johnston

Blood (2013) 121 (20): 4016–4017.

https://doi.org/10.1182/blood-2013-04-491787

Published: 2013

Journal Articles

Effectiveness and Cost of Rituximab for CLL in the Province of Manitoba Prior to Its Approval As Part of First Line Treatment

Pamela Skrabek, FRCPC, Rajat Kumar, FRCPC, James B Johnston, MD, Joseph Baptiste, MD, Bernie Lozar, Scott Streilein, Venetia Bourrier, FCSHP, Sri Navaratnam, FRCPC

Blood (2012) 120 (21): 4701.

https://doi.org/10.1182/blood.V120.21.4701.4701

Published: 2012

NARROW

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Clime: CLL Immune Micro-Environment and Risk of Infections Pre- and Post-Diagnosis: A Population-Based Study

IL-4 Mediated Upregulation of AMPK/SIRT1/PGC-1α Signalling Pathway Is Bypassed By Mitochondrial Complex I Downregulation By NAMPT Inhibition in Venetoclax and Ibrutinib Treated CLL Cells

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

Ibrutinib in Combination with Venetoclax Decreases Mitochondrial Bioenergetics through the Impaired BTK, AKT and AMPK/SIRT/PGC-1α Signaling Pathway in CLL

A Descriptive Analysis of Obinutuzumab Usage in a Single Canadian Centre

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Revelance of Gammaglobulin Levels at Diagnosis and during Disease Course in Chronic Lymphocytic Leukemia

Incidence and Implications of Skin Cancers in Cancercare Manitoba Chronic Lymphocytic Leukemia (CLL) Clinic Patients

High Cumulative Illness Rating Scale (CIRS) Score in CLL Correlates with Short CLL Telomere Length and Decreased Survival

An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Clinical Impact of Telomere Shortening in Normal and Leukemia Cells in Chronic Lymphocytic Leukemia

Lysosome Membrane Permeabilization Causes Cell Death in Primary Chronic Lymphocytic Leukemia Cells

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Jump-starting the T cells in CLL

Effectiveness and Cost of Rituximab for CLL in the Province of Manitoba Prior to Its Approval As Part of First Line Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only